

## **Predictors of poor outcome in patients diagnosed with drug-resistant tuberculosis in the Torres Strait / Papua New Guinea border region**

Foster, J<sup>1,2,3¶,#a</sup>., Mendez, D<sup>3¶</sup>., Marais, B<sup>4&</sup>., Peniyamina, D<sup>5&</sup>., McBryde, E.S.<sup>1,2,3¶,#b</sup>

<sup>1</sup>James Cook University College of Medicine and Dentistry, Townsville, Queensland, Australia

<sup>2</sup>Torres and Cape Tuberculosis Control Unit, Thursday Island, Queensland, Australia

<sup>3</sup>Australian Institute of Tropical Health and Medicine, Townsville, Queensland, Australia

<sup>4</sup>Sydney Institute for Infectious Diseases and Biosecurity, Westmead, New South Wales, Australia

<sup>5</sup>Cairns Tropical Public Health Service, Cairns, Queensland, Australia

#<sup>a</sup>Current address: James Cook University College of Medicine and Dentistry, Townsville, Queensland, Australia

#<sup>b</sup>Current address: James Cook University College of Medicine and Dentistry, Townsville, Queensland, Australia

\*Corresponding author

E-mail: [jbelle.foster@my.jcu.edu.au](mailto:jbelle.foster@my.jcu.edu.au) (JF)

¶These authors contributed equally to this work

&These authors also contributed equally to this work

## ABSTRACT

Drug-resistant tuberculosis (DR-TB) is an ongoing challenge in the Torres Strait / Papua New Guinea border region. Treatment success rates have historically been poor for patients diagnosed with DR-TB, leading to increased transmission and resistance multiplication risk. This study aimed to identify predictors of poor outcome in patients diagnosed with DR-TB to inform programmatic improvements.

A retrospective study of all DR-TB cases who presented to Australian health facilities in the Torres Strait between 1 March 2000 and 31 March 2020 was performed. This time period covers four distinct TB programmatic approaches. Univariate and multivariate predictors of poor outcome were analysed. Poor outcome was defined as treatment default, treatment failure and death (versus cure or completion).

In total, 133 patients with resistance to at least one TB drug was identified. The vast majority (123/133; 92%) of DR-TB patients had pulmonary involvement; and of these, 41% (50/123) had both pulmonary and extrapulmonary TB. Poor outcomes were observed in 29% (39/133) of patients. Patients living with human immunodeficiency virus, renal disease or diabetes (4/133; 4/133; 3/133) had an increased frequency of poor outcome ( $p < 0.05$ ), but numbers were very small. Among all 133 DR-TB patients, 41% had a low lymphocyte count, which was significantly associated with poor outcome ( $p < 0.05$ ). Overall, outcome improved in recent years with a 50% increase in the chance of a good outcome per year group over the study period; on binary logistic regression analysis. Being a close contact of a known TB case was associated with improved outcome.

While DR-TB treatment outcomes have improved over time, it remains important to prevent DR-TB spread and resistance multiplication resulting from suboptimal treatment. Enhanced surveillance for DR-TB, better cross border collaboration and consistent diagnosis and management of comorbidities and other risk factors should further improve patient care and outcomes.

## **Introduction:**

Drug resistance is a significant threat to control of tuberculosis (TB), with nearly half a million of the ten million cases in 2019 estimated to be rifampicin resistant (1). Drug-resistant (DR)-TB refers to TB strains that are resistant to any of the first-line drugs used to treat fully-susceptible (FS)-TB, any of the second-line drugs used to treat DR-TB, or are resistant to a combination of these drugs (2). Non-compliance or inadequate FS-TB treatment regimens may lead to the development of DR-TB and multidrug-resistant (MDR)-TB – that which is resistant to both isoniazid and rifampicin - which is substantially more difficult and costly to treat (3). Treatment outcomes are generally worse for DR-TB cases due to prolonged treatment regimens and severe adverse effects of TB drugs (4). Globally, the average treatment success rate in patients with MDR-TB is reported to be 50% (5) however this varies across countries (Ukraine – 18.1% (6); China – 52.2% (7); Ethiopia – 78.6%) (8).

TB is an ongoing threat in the Torres Strait / Papua New Guinea (PNG) region which is compounded by high levels of DR-TB in the Western Province of PNG and in particular, on Daru Island (9, 10) (Fig 1). The conservative incidence rate of TB in PNG is 432 / 100,000 population (WHO, 11) and 674 / 100,000 in the Western Province (12). By comparison, the incidence rate of TB over the border in Queensland, Australia is 5.5 / 100,000 population (13). In the Torres Strait Islands, 80% identify as Torres Strait Islander (14), and Indigenous Australians are disproportionately affected by TB when compared to non-Indigenous Australians (15). Significantly, residents from specific islands in the Torres Strait and villages in the Western Province of PNG share an open international border (Fig 1), heightening TB transmission risk in the region (10).

**Fig 1. Map of the Torres Strait / Papua New Guinea cross-border region (16)<sup>1</sup> CC BY 4.0**

---

<sup>1</sup> International travel without passport or visa is permitted for traditional inhabitants of the Torres Strait Protected Zone and Treaty villages of Papua New Guinea DOI. 10.6084/m9.figshare.16632823

1 Management of DR-TB is complex and is often further complicated by comorbidities with other  
2 communicable and non-communicable diseases (17). Patients with TB and coinfection /  
3 comorbidities such as renal impairment, diabetes and HIV are more likely to have poor outcomes  
4 (18-20). Many studies have reported high rates of mortality in TB patients with comorbidities (21-24)  
5 and in patients with low levels of haemoglobin, albumin and lymphocytes (25)

6 While the rise in DR-TB is a global concern, TB programs must consider specific local risk factors and  
7 programmatic gaps to ensure better outcomes for patients. These considerations may present  
8 important opportunities for TB programmes to meet the challenging targets of the WHO to End TB,  
9 aiming to reduce the incidence of TB by 90% before 2035 (26)

10 Little is known about predictors of treatment outcomes in patients diagnosed with DR-TB in the  
11 Torres Strait / PNG border region. The aim of this study was to evaluate the association of  
12 comorbidities / coinfection, the levels of a suite of serum biomarkers and the impact of  
13 programmatic changes to models of TB care over time with treatment outcomes in DR-TB patients  
14 diagnosed in the Torres Strait / PNG border region. It is the intention that evidence derived from this  
15 study will be carefully considered at a programmatic level to further improve outcomes for patients  
16 diagnosed with DR-TB in this context.

## 17 **Methods:**

### 18 **Study Design and Population**

19 This is a retrospective cohort study of 133 patients diagnosed with laboratory-confirmed DR-TB  
20 between 2000 and 2020 in the Torres Strait Islands, Australia. Pulmonary, extrapulmonary, smear  
21 positive and smear negative cases were included, as well as those with mono, poly and multidrug-  
22 resistant TB.

23 All residents of the Torres Strait Islands and residents of the PNG villages adjacent to the northern  
24 Australia / PNG border who were diagnosed in the Torres Strait with laboratory-confirmed DR-TB

25 were included in the study. Patients were excluded from the study if they were residents of PNG  
26 villages external to the Western Province of PNG who did not enter the Australian health system via  
27 a health facility in the Torres Strait Protected Zone (Fig 1).

## 28 Models of TB Care – Diagnosis and Treatment

29 There were four models of TB care provided in the region over different time periods between 2000  
30 to 2020 (2000-2005; 2006-2012; 2013-2015; 2016-2020). Across all models of TB care, the primary  
31 mode of diagnosis was via sputum collection and the collection of specimens for the diagnosis of  
32 extrapulmonary TB was rarely available in remote Australian border clinics. Isolation of  
33 mycobacterial culture, drug susceptibility testing and genotyping for specimens collected in this  
34 region were performed in the Queensland Mycobacterium Reference Laboratory in Brisbane (Fig1).  
35 (27). The major differences in care resulting from these changes were reduction in time to treatment  
36 commencement and retention in care (28).

37 Between 2000 and 2012, some treatment for DR-TB was available for PNG nationals diagnosed with  
38 DR-TB in Australian border clinics, however, access to treatment was improved between 2006 and  
39 2012 with the establishment of frequent outreach TB clinics in the Torres Strait. The change from the  
40 2000-2005 model of TB care to the 2006-2012 model of TB care was in direct response to Australian  
41 Government decisions to invest in TB management of PNG patients from two outer Torres Strait  
42 Islands, Boigu and Saibai (29). The 2013-2015 model of TB care is reflective of Government decisions  
43 to stand-down these outer island clinics and increase support and funding for TB health service  
44 coverage capability in PNG (30), thus PNG residents diagnosed from 2013 onwards were referred  
45 back to the PNG health system for treatment and management. Government decisions to invest in a  
46 local Torres Strait-based TB Control Unit with the aim of rapid response to suspected and confirmed  
47 case notifications occurred from 2016 and is ongoing (31). All Australian residents in this study were  
48 managed within the Australian healthcare system.

49

## 50 **Data Collection**

51 Queensland Health's Notifiable Conditions System (NoCS) was used to source case notification data.

52 Only cases with laboratory confirmed drug-resistant TB were included in the study, including those  
53 resistant to streptomycin. One case was added to the study where their drug-resistant status was  
54 identified in Queensland Health's laboratory software, AUSLAB but was not registered as a drug-  
55 resistant TB case in NoCS.

56 Raw data pertaining to biomarkers (haemoglobin, albumin, lymphocyte levels) were obtained from  
57 Queensland's laboratory results software, AUSLAB. These biomarkers are routinely collected in most  
58 patients presenting to primary healthcare facilities in the Torres Strait.

## 59 **Definitions**

60 Treatment outcome definitions used in the study were as per Laserson et al. (32). Poor treatment  
61 outcome was defined as death, default or treatment failure. Good treatment outcome was defined  
62 as completed treatment or cured. Other treatment outcome was defined as transfer out, to indicate  
63 that the patient had been referred back to the PNG health system. In some patients that were  
64 transferred out, treatment outcome was unknown.

65 Comorbidities / coinfection were defined as HIV, diabetes and renal impairment. In patients with  
66 comorbidities recorded as renal dysfunction, renal insufficiency, renal disease and renal failure were  
67 all defined as having renal impairment.

68 Site of disease included pulmonary TB, extrapulmonary TB or both. Case type refers to either newly  
69 diagnosed TB cases as well as those who had previously received full or partial treatment.

## 70 **Data Analyses**

71 Statistical analyses were performed using IBM SPSS Statistics, version 25 (2019, Armonk, New York,  
72 United States). Frequencies and percentages were calculated for descriptive data including age  
73 categories, sex, country of birth, visa status, primary health centre (PHC) attended, programmatic

74 diagnosis year group (Fig 2), site of disease, case type, comorbidities/coinfection, drug resistance,  
75 cough and known close contact status. Pearson's Chi-squared tests were carried out to assess  
76 whether age group, sex, country of birth, visa status, and PHC attended were associated with poor  
77 treatment outcomes.

78 Potential categorical predictors (site of disease, HIV serology, case type, comorbidities/coinfection,  
79 drug resistance and selected biomarkers including haemoglobin, lymphocytes and albumin), were  
80 analysed by poor, good or unknown treatment outcome using Fisher's Exact or likelihood ratios,  
81 except for ethionamide resistance and lymphocyte levels where Pearson Chi-Square was used to  
82 ascertain if there was a statistically significant association between these factors and treatment  
83 outcomes. Likelihood ratios, which when compared to Pearson's Chi-squared test are more likely to  
84 be Exact, were undertaken to ascertain association with poor treatment outcome for variables with  
85 more than one categorical variable. The categorical variable 'diagnostic year group' was included in  
86 the analysis as a clinical covariate to account for programmatic changes in the clinical management  
87 of TB over time.

88 Pearson's Chi-squared tests were performed to assess whether selected biomarkers (haemoglobin,  
89 lymphocyte and albumin levels) were associated with binary treatment outcomes (poor or other).  
90 Multiple imputation was not used for these analyses and numbers of patients that had biomarkers  
91 available were reported. In all univariate and multivariate logistic regression analyses, multiple  
92 imputation was applied and pooled results from five imputations were used as 19 DR-TB cases did  
93 not have any biomarker results available. Biomarker Z scores were imputed for incomplete variables  
94 and were further defined as nominal (poor or other) prior to imputation. To overcome differences in  
95 reference range parameters that were automatically applied by Queensland Health's laboratory  
96 software, AUSLAB to biomarker results based on sex and age, Z scores were calculated in Microsoft  
97 Excel (2016, North Ryde, Australia). With reference to haemoglobin levels, anaemia was defined as  
98 those with a Z score at least 2 standard deviations (SD) away from the mean, and severe anaemia



99 was defined as those with a Z score that was at least 5SD away from the mean. This resulted in our  
100 definition of anaemia fitting with the laboratory definition of below the reference range, for a given  
101 laboratory and patient profile. Similarly, low albumin and lymphocyte levels were defined as those  
102 with a Z score at least 2SD away from the mean.

103 Univariate analysis of comorbidities/coinfection, diagnosis year group, contact with a known case,  
104 biomarkers, acid-fast bacilli (AFB) positivity and rifampicin-resistance were examined as potential  
105 predictors of poor outcome using binary logistic regression. All predictor variables were considered  
106 for multivariate regression. The regression method was a forward algorithm with entry criteria of  $p <$   
107 0.05 from the univariate analyses followed by a backward algorithm with back entry criteria of  $p >$   
108 0.05. The level of significance was set at  $p < 0.05$  for all analyses.

#### 109 **Ethics**

110 The Far North Queensland Human Research Ethics Committee (HREC) (HREC/17/QCH/74-1157)  
111 approved the study, as did the Chair of James Cook University HREC, (H7380). Further approval was  
112 obtained to access case notification data via a Public Health Act application (QCH/36155 – 1157).

#### 113 **Results:**

114 Of the 133 patients with DR-TB there were 22 deaths and one failed therapy, 16 defaulted and 51  
115 were transferred out. Of the 51 that were transferred out, 41 had no known outcome. As shown in  
116 Table 1, Boigu Island PHC received fewer patients than Saibai Island PHC but had greater treatment  
117 success (49% vs 38%). The median age was 28, and patients in the 15-29 years age group were both  
118 the largest group and disproportionately affected by poor outcomes (Table 1). Eighty-three percent  
119 of older adults aged  $\geq 60$  years had a poor outcome, and of those  $> 61$  years, 100% died. There was no  
120 effect of sex on outcome. Being a PNG national rather than an Australian Torres Strait Islander was  
121 highly predictive of poor outcome.

122 **Table 1. Demographic characteristics of all patients diagnosed with drug-resistant tuberculosis in**  
 123 **the Torres Strait Islands between 2000 and 2020, and their association with good, poor and other**  
 124 **TB treatment outcomes**

Characteristic	Treatment Outcomes N = 133 (%) <sup>†</sup>						Total	P
	Good		Poor			Other		
	Cured	Completed	Died	Failed	Defaulted	Transfer Out		
<b>Age group</b>								<b>.02</b>
<5 years	2 (22)	5 (56)	0 (0)	0 (0)	0 (0)	2 (22)	9	
5-14 years	1 (10)	3 (30)	1 (10)	0 (0)	2 (20)	3 (30)	10	
15-29 years	3 (5)	21 (34)	10 (16)	0 (0)	10 (16)	18 (29)	62	
30-44 years	6 (18)	9 (27)	5 (15)	0 (0)	4 (12)	9 (27)	33	
45-59 years	0 (0)	2 (15)	2 (15)	0 (0)	0 (0)	9 (70)	13	
≥ 60 years	1 (17)	0 (0)	4 (67)	1 (17)	0 (0)	0 (0)	6	
<b>Gender</b>								<b>.7</b>
Female	9 (12)	22 (30)	14 (19)	1 (1)	8 (11)	21 (28)	75	
Male	4 (7)	18 (31)	8 (14)	0 (0)	8 (14)	20 (35)	58	
<b>Country of Birth</b>								<b>.02</b>
Australia	3 (50)	2 (33)	1 (17)	0 (0)	0 (0)	0 (0)	6	
Papua New Guinea	10 (8)	38 (30)	21 (17)	1 (1)	16 (13)	41 (32)	127	
<b>Visa Status</b>								<b>.002</b>
Australian resident	3 (33)	3 (33)	2 (22)	1 (11)	0 (0)	0 (0)	9	
Papua New Guinea Treaty Visitor	5 (6)	23 (27)	15 (17)	0 (0)	13 (15)	30 (35)	86	
Papua New Guinea non-Treaty Visitor	5 (13)	14 (37)	5 (13)	0 (0)	3 (8)	11 (29)	38	
<b>Primary Health Centre Attended</b>								<b>.98</b>
Saibai Island	11 (10)	32 (29)	19 (17)	1 (1)	14 (13)	33 (30)	110	
Boigu Island	2 (13)	7 (44)	2 (13)	0 (0)	2 (13)	3 (19)	16	
Murray Island	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)	2	
Darnley Island	0 (0)	1 (50)	0 (0)	0 (0)	0 (0)	1 (50)	2	
Yorke Island	0 (0)	0 (0)	1 (50)	0 (0)	0 (0)	1 (50)	2	
Thursday Island	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	1	

125 <sup>†</sup> Percentages may not equal 100 due to rounding.

126

127 Table 2 shows that DR-TB patients diagnosed between 2000 and 2005 were more likely to have poor  
 128 outcomes (50%) than those diagnosed between 2016 and 2020 (17%). Of 133 cases of DR-TB, 67%  
 129 had MDR-TB and of those, 74% ( $n = 66$ ) were new cases and 32% had a poor outcome. Ethionamide  
 130 resistance was only identified in patients diagnosed with MDR-TB ( $p < .001$ ) and 90% of MDR-TB  
 131 cases were ethionamide resistant. Nearly one in five patients had previously received full or partial  
 132 treatment in Australia or PNG. The composite variable for comorbidities/coinfection were comprised  
 133 of four DR-TB / HIV coinfection cases, three DR-TB / diabetes comorbidity cases and four DR-TB /  
 134 renal comorbidity cases. Seventy-five percent of patients with DR-TB/HIV coinfection died, and 100%  
 135 of patients with DR-TB/diabetes comorbidity died. Overall, 78% of patients with DR-TB and at least  
 136 one coinfection/comorbidity had a poor outcome.

137 **Table 2. Clinical variables of patients diagnosed with drug-resistant tuberculosis in the Torres**  
 138 **Strait between 2000 and 2020, and their association with good, poor and other TB treatment**  
 139 **outcome**

Variable	Treatment Outcome N = 133 (% of total)				P
	Poor (N = 39; 29%)	Good (N = 53; 40%)	Other (N = 41; 31%)	Total	
<b>Diagnosis Year Group*</b>				133	<b>.045</b>
2000-2005	7 (50)	5 (36)	2 (14)	14	
2006-2012	26 (27)	37 (39)	33 (34)	96	
2013-2015	4 (36)	2 (18)	5 (46)	11	
2016-2020	2 (17)	9 (75)	1 (8)	12	
<b>Disease Site</b>				133	<b>.08</b>
Pulmonary TB	25 (34)	22 (30)	26 (36)	73	
Extrapulmonary TB	2 (20)	7 (50)	1 (10)	10	
Both PTB and XPTB	12 (24)	24 (48)	14 (28)	50	
<b>Case Type</b>				133	<b>.2</b>
New	29 (27)	41 (38)	37 (35)	107	
Full or partial treatment overseas	8 (38)	11 (52)	2 (10)	21	
Full or partial treatment in Australia	2 (40)	1 (20)	2 (40)	5	
<b>Comorbidities / Coinfection</b>				133	<b>.003</b>
Diabetes Mellitus, Renal Disease or HIV	7 (78)	0	2 (22)	9	
No known risk factors	32 (26)	53 (43)	39 (32)	124	

<b>Drug Resistance</b>				133	<b>.04</b>
Isoniazid (mono)	5 (14)	16 (46)	14 (40)	35	
Rifampicin (mono)	3 (75)	1 (25)	0	4	
MDR-TB	29 (33)	33 (37)	27 (30)	89	
Other (streptomycin mono)	2 (40)	3 (60)	0	5	
<b>Ethionamide</b>				133	<b>.8</b>
Ethionamide resistant	24 (30)	30 (38)	26 (33)	80	
Susceptible	15 (28)	23 (43)	15 (28)	53	
<b>Cough</b>				114	<b>.1</b>
Cough	27 (31)	31 (36)	29 (33)	87	
No cough	4 (15)	15 (56)	8 (30)	27	
<b>Close Contact<sup>#</sup></b>				133	<b>.02</b>
Close contact	8 (16)	23 (45)	20 (39)	51	
No known contact	31 (38)	30 (37)	21 (26)	82	

140 Note. poor outcome - died, failed, defaulted; good outcome - cured, completed treatment; other -  
141 transferred out

142 \*Diagnosis year group was included as a variable due to changes in the clinical management of DR-  
143 TB patients over time.

144 <sup>#</sup>Close contact to a known TB case as reported by patient.

145 PTB, pulmonary TB; XPTB, extrapulmonary TB; MDR-TB, multidrug-resistant TB.

146 Table 3 shows that 86% of patients with haemoglobin recorded had anaemia, and of those, 38% had

147 severe anaemia. Low albumin was detected in 76% of patients that had levels recorded. In patients

148 with low lymphocyte levels, 44% of patients had a poor outcome.

149 **Table 3. Blood test abnormalities in patients diagnosed with drug-resistant tuberculosis in the**  
150 **Torres Strait between 2000 and 2020, and their association with treatment outcome**

Variable	Treatment Outcome n (%)			
	Poor	Other	Total	P
<b>Haemoglobin Levels* (50-146L)</b>			107	<b>.5</b>
No anaemia	3 (20)	12 (80)	15	
Mild anaemia	20 (35)	37 (65)	57	
Severe anaemia	10 (29)	25 (71)	35	
<b>Lymphocyte count<sup>#</sup> (0.04-9.80L)</b>			106	<b>.01</b>
Normal	13 (21)	50 (79)	63	
Low	19 (44)	24 (56)	43	
<b>Albumin<sup>#</sup> (&lt;15-48L)</b>			105	<b>.07</b>

Other (normal or high)	4 (16)	21 (84)	25	
Low	28 (35)	52 (65)	80	

151 \*Mild anaemia, at least 2 standard deviations (SD) away from the mean; severe anaemia, at least  
152 5SD away from the mean; #Low lymphocyte and albumin, at least 2SD away from the mean.

153 In Table 4, patients with comorbidities / coinfection, low lymphocyte levels and AFB positivity were  
154 significantly more likely to have poor outcomes. Being a close contact of a known TB case was a  
155 protective factor and reduced the odds of a poor outcome occurring ( $p$  .008; OR .31). Although the  $p$   
156 value for anaemia in Table 3 was  $> .1$ , this variable was included in the univariate analysis as other  
157 studies have demonstrated an association between anaemia and poor outcomes (33), however in  
158 this study, anaemia was not a significant predictor of poor outcomes. In the adjusted multivariate  
159 model, comorbidities / coinfection, being a close contact of a known TB case and low lymphocyte  
160 levels retained significance ( $p < 0.05$ ).

161 **Table 4. Predictors of poor treatment outcome among drug-resistant tuberculosis cases diagnosed**  
162 **in the Torres Strait / Papua New Guinea border region between 2000 and 2020 (n = 133)**

Variable	N (%)	Univariate Analysis		Multivariate Analysis	
		OR (95% CI)	p-value	aOR (95% CI)	p-value
Comorbidities / Coinfection (DM, renal, HIV)	9 (7)	10.06 (1.98-50.96)	.005	17.4 (2.6-117.06)	.003
Contact with known TB case	51 (38)	.31 (.12-.73)	.008	.3 (.08-.87)	.03
Low lymphocyte level	43 (32)	3.05 (1.29-7.17)	.01	2.7 (1.1-7.08)	.04
AFB positive	80 (60)	2.4 (1.07-5.58)	.03	1.6 (.56-4.48)	.4
Rifampicin resistance	93 (70)	2.5 (.96-6.21)	.05	Eliminated at forward step	
Anaemia	93 (70)	1.9 (.50-7.26)	.3	Eliminated at forward step	
Low albumin level	80 (60)	2.8 (.88-9.05)	.08	Eliminated at forward step	
Female sex	75 (56)	1.2 (.55-2.47)	.7	Eliminated at forward step	

163 Note. aOR, adjusted odds ratio; CI, confidence interval; DM, diabetes mellitus; renal, renal  
164 impairment; HIV, human immunodeficiency virus; AFB, acid-fast bacilli.

165 **Discussion:**

166 This is the first study, to the best of our knowledge, to identify predictors of poor treatment  
167 outcomes in patients diagnosed with DR-TB and examine the impact of four different models of TB  
168 care over two decades in the Torres Strait / PNG border region. We found a 50% improvement in  
169 good treatment outcomes under the model of care involving a local TB unit from 2016 compared  
170 with earlier models. Patients diagnosed before 2013 were significantly more likely to have poor  
171 treatment outcomes in this study and this is reflective of a time when accessibility to mycobacterial  
172 culture and drug susceptibility testing was not routinely available on Daru Island in PNG, and where  
173 access to second line drugs was only available for PNG nationals in this study via Australian TB clinics  
174 (34). For patients diagnosed between 2013 and 2015 in this study, a higher proportion had an  
175 unknown outcome. This is consistent with the changeover from the 2006 to 2012 TB management  
176 model of increased surveillance and detection at border clinics, to a handover period whereby PNG  
177 patients diagnosed at Australian border health facilities were referred back to the PNG health  
178 system for ongoing management and care.

179 From 2016 onwards, TB clinicians were based in the Torres Strait and therefore able to rapidly  
180 respond to cases diagnosed, associated contact tracing efforts and monitoring of treatment  
181 compliance and outcomes for patients. Higher success rates for DR-TB patients have been reported  
182 in countries where patients have access to developed health infrastructure and where skilled  
183 clinicians are positioned to support DR-TB patients (35). From 2016, local nurses and Indigenous  
184 Health Workers undertook Directly Observed Therapy for TB patients residing in the Torres Strait.  
185 Collegial relationships between TB programs in the Torres Strait and Daru Island were also  
186 strengthened through this period with the joint development of procedural documents and  
187 processes (36) which enabled each TB program to define data requirements, streamline the  
188 exchange of shared patient information, and enhance surveillance capability. These initiatives are  
189 consistent with the Australian National Tuberculosis Advisory Committee recommendations to  
190 engage in regional and bilateral collaborations in order to improve TB services in high-risk areas (37).

191 This study also found that close contacts of previous TB cases were afforded a protective factor  
192 against poor treatment outcomes. It is widely accepted that household contacts of DR-TB patients  
193 are at greater risk of exposure, infection and disease progression when compared with other types  
194 of contacts (38). In a study of MDR-TB index cases in Pakistan, MDR-TB diagnoses were reported in  
195 17.4% of close contacts (38). Unlike isoniazid-resistant TB which is more amenable to treatment,  
196 patients with both isoniazid and rifampicin resistance may be more likely to remain infectious longer  
197 than patients with DS-TB (39), thus increasing the likelihood of transmission to close contacts.  
198 Despite the increased transmission risk, close contacts had more favourable outcomes in this study.  
199 A possible explanation is that these close contact patients were linking in with healthcare services  
200 earlier, perhaps while accompanying previously diagnosed household members to clinic  
201 appointments. Better outcomes for close contacts after 2014 may also be attributed to improved  
202 health literacy and symptom recognition as a result of mass community education offered in the  
203 region from 2014 (40).

204 A limitation in this study is that it did not identify the type of close contact (i.e. household contact),  
205 nor ascertain the type of TB that each close contact was exposed to. The recent upgrade of the  
206 Mabadauan health centre in PNG will aid the PNG health system's capacity to manage close contacts  
207 in border communities. It will, however, be important that expanded diagnostic capabilities at  
208 Mabadauan, are matched with capacity to retain patients in the TB care pathway (35). Since 2016,  
209 the Torres and Cape TB Control Unit has collected and shared TB contact tracing data with Daru  
210 General Hospital, related to all PNG residents diagnosed with TB in the Torres Strait. It is anticipated  
211 that increased capacity of local health services available to residents of PNG living adjacent to the  
212 Torres Strait, may lead to effective TB contact management, further improve treatment outcomes  
213 for PNG patients diagnosed with DR-TB as well as support TB patients with other  
214 comorbidities/coinfection.

215 Another potential limitation of this study is that only people with TB isolates with at least one  
216 frontline drug resistance was included. Hence the full impact of MDR treatment (compared with fully  
217 susceptible TB) could not be evaluated. We were however able to compare those with and without  
218 rifampicin resistance, finding a trend to worse outcome.

219 Patients with pre-existing comorbidities/coinfection in this study were significantly more likely to  
220 have poor treatment outcomes. This finding is consistent with that of other studies that report  
221 worse treatment outcomes for patients with comorbidities/coinfection (6, 41, 42). In our study, no  
222 patients with a reported comorbidity/coinfection were cured or completed treatment. One hundred  
223 percent of patients with DR-TB/diabetes comorbidity died and 75% of patients with TB/HIV  
224 coinfection had a poor outcome, and this is cause for concern. While HIV is a very strong predictor  
225 for the development of active TB disease, HIV is unlikely to be a major contributing factor in TB  
226 transmission dynamics in the region as currently less than 1% of the population is infected (43).  
227 Regardless, the high proportion of poor treatment outcomes in patients with TB/HIV coinfection  
228 suggests routine HIV testing is warranted for all patients diagnosed with TB in this setting. It is also  
229 possible that 'stand-alone' or vertical disease programs of TB control, diabetes management and  
230 sexual health in the current health system may contribute to poor outcomes for coinfecting patients  
231 (44). To help mitigate poor outcomes in patients with DR-TB/diabetes and DR-TB/HIV coinfection, it  
232 may be beneficial for TB programs to establish linkages with both diabetes educators and sexual  
233 health providers to provide enhanced screening, monitoring and management of patients with these  
234 comorbidities / coinfection (45). As there were no protocols in places to consistently screen TB  
235 patients for diabetes or renal impairment during this study period, it is possible that comorbidities  
236 have been under-reported in this study.

237 Aboriginal and Torres Strait Islander peoples develop chronic kidney disease three times as often as  
238 non-Indigenous Australians (46) and in Torres Strait Islander adults, a recent survey found that  
239 nearly one in five people showed signs and symptoms of chronic kidney disease (47). In renal



240 patients, delayed diagnosis of TB is a possible reason for poor prognosis (24). As uremic symptoms  
241 like fever and weight loss are non-specific symptoms of both TB and renal disease, renal physicians  
242 would be well placed to consider TB as a differential diagnosis and monitor patients with insidious  
243 onset of these symptoms (24). Early detection of TB in renal patients may be key to improved  
244 outcomes (24). Efforts to increase collaboration between renal and TB units in the Torres Strait may  
245 help reduce diagnostic delay and better support shared patients.

246 In this study, we also evaluated low serum haemoglobin, albumin and lymphocyte levels as  
247 predictors of poor outcomes of DR-TB. Our findings show that low lymphocyte levels are statistically  
248 significantly associated with poor treatment outcomes in DR-TB patients, consistent with other  
249 studies (48). In patients that have had TB for sustained periods such as those with previous  
250 treatment default or failure, overall health decline evidenced by low lymphocyte levels can be a  
251 marker for severity of TB disease which can be more complex to manage (49). When compared to  
252 FS-TB, lower lymphocyte counts have been reported in MDR-TB patients (50). Low lymphocyte  
253 levels, AFB positivity, and skewed distribution of low haemoglobin and low albumin levels in DR-TB  
254 cases, are all representative of poor health at diagnostic baseline, as were observed in this study.

255 In other studies, serum haemoglobin and albumin were strong predictors of mortality (51) and in  
256 China and Israel, an association between hypoalbuminaemia and poor prognosis in DR-TB patients  
257 has been reported (7, 52). Further, a study conducted in Ethiopia reported that MDR-TB patients  
258 with low haemoglobin levels (anaemia) were more than twice as likely to have poor treatment  
259 outcomes when compared to patients without anaemia (41). Although anaemia and  
260 hypoalbuminaemia were not statistically significantly associated with poor outcomes for DR-TB  
261 patients in this study, it is unlikely that this was due to clinical manifestations of disease and more  
262 likely a power issue as nearly all patients in this study were anaemic and hypoalbuminaemic. Low  
263 haemoglobin has been associated with poor outcomes in TB patients, as well as delayed sputum  
264 conversion at two months (53). This may help to explain the significant association in this study

265 between poor outcomes and patients with AFB positive DR-TB, although this study did not examine  
266 timing of sputum conversion. It is possible that the cause of anaemia in DR-TB patients is due to iron  
267 nutritional deficiency (33), however this study did not explore levels of iron, ferritin, hepcidin and  
268 transferrin.

#### 269 Limitations

270 Our study has several limitations, some of which have been described above. Additionally, this study  
271 only included DR-TB patients which may have impacted the power of statistical analyses. Future  
272 studies could incorporate drug-susceptible patients in the same periods to use as a comparator. We  
273 were unable to ascertain whether the cause of death for all patients was TB, however, patient death  
274 was documented during the time period for the course of TB treatment for all patients.

#### 275 Conclusion

276 Although having a locally-based TB program in the Torres Strait has resulted in better treatment  
277 outcomes for DR-TB patients, interventions to both reduce the likelihood of poor outcomes and  
278 refine the focus on maximising treatment completion in vulnerable sub-population groups at risk of  
279 poor outcomes are needed. Comorbidities and poor health indicators at diagnosis show that DR-TB  
280 is occurring in vulnerable populations. These findings have important implications for TB programs  
281 on both sides of this international border where DR-TB is prevalent, and there are multiple  
282 operational modifications worth consideration. Routine incorporation of key strategies should  
283 include collaborative working relationships with diabetes/renal/sexual health care providers to  
284 consistently identify and manage TB in patients with comorbidities, enhanced cross border  
285 collaboration and ongoing commitment to point of care HIV and baseline blood testing that may  
286 help to flag DR-TB patients at-risk of poor outcomes.

287

288

## 289 REFERENCES


- 290 1. World Health Organization. Global tuberculosis report. Geneva, Switzerland: World Health  
291 Organization; 2020.
- 292 2. World Health Organization (WHO). WHO treatment guidelines for drug-resistant  
293 tuberculosis. Geneva, Switzerland: World Health Organization; 2016.
- 294 3. Jenkins HE, Crudu V, Soltan V, Ciobanu A, Domente L, Cohen T. High risk and rapid  
295 appearance of multidrug resistance during tuberculosis treatment in Moldova. *European Respiratory*  
296 *Journal*. 2014;43:1132-41.
- 297 4. Sagwa E, Ruswa N, Musasa JP, Mantel-Teeuwisse AK. Adverse events during treatment of  
298 drug-resistant tuberculosis: A comparison between patients with or without human  
299 immunodeficiency virus co-infection. *Drug Safety*. 2013;36:1087–96.
- 300 5. Nair D, Velayutham B, Kannan T, Tripathy JP, Harries AD, Natrajan M, et al. Predictors of  
301 unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. *Public*  
302 *Health Action*. 2017;7(1):32-8.
- 303 6. Aibana O, Bachmaha M, Krasiuk V, Rybak N, Flanigan TP, Petrenko V, et al. Risk factors for  
304 poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. *Biomed Central*  
305 *Infectious Diseases*. 2017;17(129).
- 306 7. Tang S, Tan S, Yao L, Li F, Li L, Guo X, et al. Risk Factors for Poor Treatment Outcomes in  
307 Patients with MDR-TB and XDR-TB in China: Retrospective Multi-Center Investigation. *PLOS ONE*.  
308 2013;8(12).
- 309 8. Meressa D, Hurtado RM, Andrews JR, Diro E, Abato K, Daniel T, et al. Achieving high  
310 treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in  
311 Ethiopia—an observational cohort study. *Biomed Journal Thorax*. 2015;70(12).
- 312 9. Furin J, Cox H. Outbreak of multidrug-resistant tuberculosis on Daru Island. *Lancet*  
313 *Respiratory Medicine*. 2016;4(5):347-9.
- 314 10. Baird T, Donnan, E., Coulter, C., Simpson, G., Konstantinos, A., Eather, G. . Multidrug-  
315 resistant tuberculosis in Queensland, Australia: an ongoing cross-border challenge. *International*  
316 *Journal of Tuberculosis and Lung Disease*. 2018;22(2):206-11.
- 317 11. World Health Organization. TB country profile - Papua New Guinea. Geneva, Switzerland:  
318 World Health Organization; 2016.
- 319 12. Aia P, Wangchuk L, Morishita F, Kisomb J, Yasi R, Kal M, et al. Epidemiology of tuberculosis in  
320 Papua New Guinea: analysis of case notification and treatment-outcome data, 2008-2016. *Western*  
321 *Pacific Surveillance and Response Journal*. 2018;9(2):9-19.
- 322 13. Viney K. The Australian tuberculosis risk factor survey Canberra, Australia: Australian  
323 National University; 2021.
- 324 14. Australian Bureau of Statistics. Changing characteristics of the Torres Strait region and its  
325 people. Canberra, Australia: Australian Bureau of Statistics,; 2018.
- 326 15. Robertus LM, Konstantinos A, Hayman NE, Paterson DL. Tuberculosis in the Australian  
327 indigenous population: History, current situation and future challenges. *Australian and New Zealand*  
328 *Journal of Public Health*. 2011;35(1):6-9.
- 329 16. Moran M, Foster J, Mendez D, cartographers. Map of the Torres Strait / Papua New Guinea  
330 cross-border region. Cairns, Queensland 2021. DOI. 10.6084/m9.figshare.16632823.
- 331 17. Esmail A, Sabur NF, Okpechi I, Dheda K. Table Bloods. Biomarkers in patients diagnosed with  
332 drug-resistant TB in the Torres Strait between 2000 and 2020, stratified by treatment outcome.  
333 *Journal of Thoracic Disease*. 2018;10(5).
- 334 18. Chung-Delgado K, Guillen-Bravo S, Revilla-Montag A, Bernabe-Ortiz A. Mortality among  
335 MDR-TB Cases: Comparison with Drug-Susceptible Tuberculosis and Associated Factors. *PLOS ONE*.  
336 2015;10(3).
- 337 19. Bhering M, Duarte R, Kritski A. Predictive factors for unfavourable treatment in MDR-TB and  
338 XDR-TB patients in Rio de Janeiro State, Brazil, 2000-2016. *PLOS ONE*. 2019;14(11).

- 339 20. Gómez-Gómez A, Magaña-Aquino M, López-Meza S, Aranda-Álvarez M, Díaz-Ornelas DE,  
340 Guadalupe Hernández-Segura M, et al. Diabetes and Other Risk Factors for Multi-drug Resistant  
341 Tuberculosis in a Mexican Population with Pulmonary Tuberculosis: Case Control Study. *Archives of*  
342 *Medical Research*. 2015;46(2).
- 343 21. Lui SL, Tang S, Li FK, Choy BY, Chan TM, Lo WK, et al. Tuberculosis infection in Chinese  
344 patients undergoing continuous ambulatory peritoneal dialysis. *American Journal of Kidney Disease*.  
345 2001;38:1055-60.
- 346 22. Taskapan H, Utas C, Oymak FS, Gulmez I, Ozesmi M. The outcome of tuberculosis in patients  
347 on chronic hemodialysis. *Clinical Nephrology*. 2000;54:134-7.
- 348 23. Moore DA, Lightstone L, Javid B, Friedland JS. High rates of tuberculosis in end-stage renal  
349 failure: the impact of international migration. *Emerging Infectious Disease*. 2002;8:77-8.
- 350 24. Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and Chronic Renal Disease. *Seminars in*  
351 *Dialysis*. 2003;16(1):38-44.
- 352 25. Rarau P, Guo S, Baptista SN, Pulford J, McPake B, Oldenburg B. Prevalence of non-  
353 communicable diseases and their risk factors in Papua New Guinea: A systematic review. *SAGE Open*  
354 *Medicine*. 2020;8.
- 355 26. World Health Organization (WHO). WHO End TB Strategy. Geneva: Switzerland: World  
356 Health Organization; 2015.
- 357 27. Bainomugisa A, Pandey S, Donnan E, Simpson G, Foster J, Lavu E, et al. Cross-border  
358 movement of a highly drug resistant Mycobacterium tuberculosis strain identified in the Torres  
359 Strait, Australia. *Emerging Infectious Disease* 2019;25(3).
- 360 28. Foster J, Mendez D, Marais B, Peniyamina D, McBryde ES. Time to commencement of  
361 effective treatment in patients with drug-resistant tuberculosis diagnosed in the Torres Strait /  
362 Papua New Guinea cross-border region. medRxiv. 2022.
- 363 29. Vincent SD. A clinician's perspective on providing TB services in the Torres Strait. *Medical*  
364 *Journal of Australia*. 2011;195(9):506-7.
- 365 30. Marais B, Sorrell T, Brittle W. Drug-resistant tuberculosis in PNG and Torres Strait islands.  
366 *The Conversation*. 2012.
- 367 31. Queensland Health. Tuberculosis (TB) Control: Torres and Cape Hospital and Health Service;  
368 2016 [Available from: <https://www.health.qld.gov.au/torres-cape/html/tuberculosis>].
- 369 32. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the  
370 same language: treatment outcome definitions for multidrug-resistant tuberculosis. *International*  
371 *Journal of Tuberculosis and Lung Disease*. 2005;9(6):640-5.
- 372 33. de Mendonça EB, Schmaltz CA, Sant'Anna FM, Vizzoni AG, Mendes-de-Almeida DP, et al.  
373 Anemia in tuberculosis cases: A biomarker of severity? *PLOS ONE*. 2021;16(2).
- 374 34. Simpson G. Multidrug-resistant tuberculosis on Australia's northern border. *National Library*  
375 *of Medicine*. 2011;41(11):759-61.
- 376 35. Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M, Linh N, et al. Multidrug-resistant  
377 tuberculosis around the world: what progress has been made? *European Respiratory Journal*.  
378 2015;45(1):150-60.
- 379 36. Torres and Cape Hospital and Health Service. Procedure: Management of Papua New Guinea  
380 Nationals accessing healthcare within the Australian Islands of the Torres Strait Protected Zone,  
381 presumed to have or diagnosed with tuberculosis. Torres and Cape Hospital and Health Service;  
382 2017.
- 383 37. National Tuberculosis Advisory Committee. The Strategic Plan for Control of Tuberculosis in  
384 Australia, 2016–2020: Towards Disease Elimination. The National Tuberculosis Advisory Committee  
385 for the Communicable Diseases Network Australia Communicable Diseases Intelligence.  
386 2018;2019(43):1-19.
- 387 38. Javaid A, Khan MA, Khan MA, Mehreen S, Basit A, Khan RA, et al. Screening outcomes of  
388 household contacts of multidrug-resistant tuberculosis patients in Peshawar, Pakistan. *Asian Pacific*  
389 *Journal of Tropical Medicine*. 2016;9(9):909-12.

- 390 39. Khan MA, Mehreen S, Basit A, Khan RA, Jan F, Ullah I. Characteristics and treatment  
391 outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar,  
392 Pakistan. *Saudi Medical Journal*. 2015;36(12):1463.
- 393 40. Torres and Cape Hospital and Health Service. TB education in PNG treaty villages. Cairns,  
394 Queensland 2015.
- 395 41. Alene KA, Viney K, McBryde ES, Tsegaye AT, Clements ACA. Treatment outcomes in patients  
396 with multidrug-resistant tuberculosis in north-west Ethiopia. *Tropical Medicine & International*  
397 *Health*. 2016;22(3):351-62.
- 398 42. Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The impact of diabetes on  
399 tuberculosis treatment outcomes: A systematic review. *BioMed Central Medicine*. 2011;9(81).
- 400 43. Viney K, O'Connor J, Wiegandt A. The epidemiology of tuberculosis in pacific island countries  
401 and territories: 2000-2007. *Asia Pacific Journal of Public Health*. 2011;23(1):86-99.
- 402 44. Bates M, Marais BJ, Zumla A. Tuberculosis Comorbidity with Communicable and  
403 Noncommunicable Diseases. *Perspectives in Medicine*. 2015;11(6).
- 404 45. Marais BJ, Lönnroth K, Lawn SD, Migliori GB, Mwaba P, Glaziou P, et al. Tuberculosis  
405 comorbidity with communicable and non-communicable diseases: integrating health services and  
406 control efforts. *Lancet Infectious Diseases*. 2013;13:436-48.
- 407 46. Australian Department of Health. What we're doing about kidney disease Canberra,  
408 Australia: Australian Department of Health. 2020 [Available from:  
409 [https://www.health.gov.au/health-topics/chronic-conditions/what-were-doing-about-chronic-](https://www.health.gov.au/health-topics/chronic-conditions/what-were-doing-about-chronic-conditions/what-were-doing-about-kidney-disease)  
410 [conditions/what-were-doing-about-kidney-disease](https://www.health.gov.au/health-topics/chronic-conditions/what-were-doing-about-chronic-conditions/what-were-doing-about-kidney-disease).
- 411 47. Australian Institute of Health and Welfare. Profiles of Aboriginal and Torres Strait Islander  
412 people with kidney disease. Canberra, Australia: Australian Institute of Health and Welfare. 2020.  
413 Report No.: 978-1-76054-712-7 Contract No.: Cat. no: IHW 229.
- 414 48. Chedid C, Kokhreizdec E, Tukvadze N, Banud S, Khaja M, Uddind M, et al. Association of  
415 baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered  
416 cohort study. *International Journal of Infectious Diseases*. 2020;100:199-206.
- 417 49. Panteleev AV, Nikitina IY, Burmistrova IA, Kosmiadi GA, Radaeva TV, Amansahedov RB, et al.  
418 Severe Tuberculosis in Humans Correlates Best with Neutrophil Abundance and Lymphocyte  
419 Deficiency and Does Not Correlate with Antigen-Specific CD4 T-Cell Response. *Frontiers in*  
420 *Immunology*. 2017;21(8):963.
- 421 50. Kiran B, Cagatay T, Clark P, Kosar F, Cagatay P, Yurt S, et al. Can immune parameters be used  
422 as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis?  
423 *Archives of Medical Science*. 2010;6(1):77-82.
- 424 51. Mehta JB, Fields CL, Byrd Jr RP, Roy TM. Nutritional status and mortality in respiratory failure  
425 caused by tuberculosis. *Journal of the Tennessee Medical Association*. 1996;89(10):369-71.
- 426 52. Bendayan D, Hendler A, Polansky V, Weinberger M. Outcome of hospitalized MDR-TB  
427 patients: Israel 2000–2005. *European Journal of Clinical Microbiology and Infectious Diseases*.  
428 2011;30:375-9.
- 429 53. Nagu TJ, Spiegelman D, Hertzmark E, Aboud S, Makani J, Matee MI, et al. Anemia at the  
430 Initiation of Tuberculosis Therapy Is Associated with Delayed Sputum Conversion among Pulmonary  
431 Tuberculosis Patients in Dar-es-Salaam, Tanzania. *PLOS ONE*. 2014;9(3).

432

433



medRxiv preprint doi: <https://doi.org/10.1101/2022.03.22.22272751>; this version posted March 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



Figure